These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24335564)

  • 1. Potential for biomarkers of chronic kidney disease-mineral bone disorder to improve patient care.
    Alderson HV; Ritchie JP; Green D; Chiu D; Kalra PA
    Nephron Clin Pract; 2013; 124(3-4):141-50. PubMed ID: 24335564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone disease in CKD: a focus on osteoporosis diagnosis and management.
    Miller PD
    Am J Kidney Dis; 2014 Aug; 64(2):290-304. PubMed ID: 24726630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease-mineral and bone disorder KDIGO guidelines.
    Khwaja A
    Nephron Clin Pract; 2010; 116(1):c25-6. PubMed ID: 20460936
    [No Abstract]   [Full Text] [Related]  

  • 4. Bone alkaline phosphatase in CKD-mineral bone disorder.
    Sardiwal S; Magnusson P; Goldsmith DJ; Lamb EJ
    Am J Kidney Dis; 2013 Oct; 62(4):810-22. PubMed ID: 23623575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in native and transplant kidneys: opportunities to improve prediction of outcomes in chronic kidney disease.
    De Serres SA; Varghese JC; Levin A
    Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):619-27. PubMed ID: 22914685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.
    Delanaye P; Souberbielle JC; Lafage-Proust MH; Jean G; Cavalier E
    Nephrol Dial Transplant; 2014 May; 29(5):997-1004. PubMed ID: 23868144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease.
    Staude H; Jeske S; Schmitz K; Warncke G; Fischer DC
    Kidney Blood Press Res; 2013; 37(1):68-83. PubMed ID: 23548827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management.
    Lewis R
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Magnesium disorder and its clinical significance in chronic kidney disease].
    Okuno S
    Clin Calcium; 2012 Aug; 22(8):1243-9. PubMed ID: 22846361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnesium in chronic kidney disease: unanswered questions.
    Spiegel DM
    Blood Purif; 2011; 31(1-3):172-6. PubMed ID: 21228586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone health in chronic kidney disease-mineral and bone disease.
    Gal-Moscovici A; Sprague SM
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: Managing bone complications after kidney transplantation.
    Mainra R; Elder G
    Nephrology (Carlton); 2009 Jun; 14(4):437-42. PubMed ID: 19563386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and management of chronic kidney disease complications by internal medicine residents: a national survey.
    Agrawal V; Agarwal M; Ghosh AK; Barnes MA; McCullough PA
    Am J Ther; 2011 May; 18(3):e40-7. PubMed ID: 19918169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary phosphorus and kidney disease.
    Uribarri J
    Ann N Y Acad Sci; 2013 Oct; 1301():11-9. PubMed ID: 23876096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations for mineral and bone disorder in chronic kidney disease].
    Staszków M; Przedlacki J
    Wiad Lek; 2014; 67(3):422-5. PubMed ID: 25782204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
    Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
    Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).
    Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M
    Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.